Stallergenes Greer Expands into the Nordic Region
Stallergenes Greer, a prominent name in allergen immunotherapy (AIT), is thrilled to announce its expansion into the Nordic region by establishing an affiliate dedicated to serving the Danish, Norwegian, and Swedish markets. This endeavor, known as Stallergenes Greer Danmark ApS, aims to deliver a fully registered portfolio of sublingual tablet treatments specially designed for grass pollen and house dust mite-induced allergic rhinitis.
The Prevalence of Allergic Rhinitis in Europe
Allergic rhinitis currently affects approximately 1 in 5 individuals in Europe, with a staggering 19% prevalence rate that has been on the rise for several decades. The primary culprits of this condition are often aeroallergens like pollen and house dust mites. These allergens can lead to nasal and ocular symptoms that significantly impact daily activities and may exacerbate into allergic asthma—a serious chronic condition affecting 15% to 38% of patients living with allergic rhinitis.
Commitment to Improving Patient Lives
Brice Chouquet, the Country Manager for the Nordic region, expressed the company's enthusiasm: "We are delighted to enter the Nordic region and contribute to improving the quality of life for patients with grass pollen and house dust mite allergies. With the establishment of Stallergenes Greer Danmark ApS, allergy sufferers and physicians in Denmark, Norway, and Sweden can rely on our commitment to provide effective, high-quality, and clinically validated allergen immunotherapy treatments." The expansion is part of a broader strategy, with Finland set to follow in 2025.
Stallergenes Greer's Dedication to Allergy Care
This geographic expansion underscores Stallergenes Greer’s unwavering commitment to delivering comprehensive allergy care solutions to patients and healthcare professionals worldwide. With nearly 120 years of experience in the field of allergy and allergen immunotherapy, Stallergenes Greer has cultivated a vast global presence and maintains significant manufacturing capabilities for allergen and finished AIT products. The company continuously strives to meet the specific needs of allergy sufferers through innovative treatment options.
About Stallergenes Greer Danmark ApS
Stallergenes Greer Danmark ApS operates as a subsidiary of Stallergenes Greer AG, a global healthcare company based in Baar, Switzerland. They specialize in diagnosing and treating respiratory, food, and venom allergies via allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company to both Greer Laboratories, Inc. and Stallergenes SAS, reinforcing the company's wide-reaching impact in the field of allergy care.
Looking Ahead
As Stallergenes Greer looks to the future, the company aims to further its efforts in enhancing the quality of life for patients battling allergies. The establishment of their new Nordic affiliate signifies an important step in making effective treatment options more accessible to those in need.
Frequently Asked Questions
1. What is Stallergenes Greer?
Stallergenes Greer is a global leader in allergen immunotherapy, focused on developing and providing solutions for allergy sufferers.
2. What services does Stallergenes Greer Danmark ApS provide?
The affiliate offers a range of sublingual tablet treatments addressing grass pollen and house dust mite-induced allergic rhinitis.
3. Why is allergic rhinitis prevalent in Europe?
Factors such as environmental changes and increased exposure to allergens contribute to the rising prevalence of allergic rhinitis.
4. How does Stallergenes Greer's expansion benefit patients?
The expansion makes allergy treatments more accessible, providing patients with high-quality, clinically proven solutions in the Nordic region.
5. When will Finland see Stallergenes Greer’s services?
Stallergenes Greer plans to expand its services to Finland in 2025, further increasing its reach in the Nordic region.
